Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn

This article was originally published here

As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment

The post Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply